| Budget Amount *help |
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2013: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2012: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2011: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2010: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
|
|---|
| Research Abstract |
In order to develop a new alveolar type II epithelial cell model, Abca3 gene was introduced into RLE-6TN cells. Compared to RLE-6TN cells, the expression of Abca3 mRNA and the formation of lamellar bodies, characteristic intracellular organelle in type II cells, were increased in RLE/Abca3 cells. Surprisingly, the expression of other type II marker mRNAs and albumin uptake activity were also increased, indicating that introduction of Abca3 gene would direct RLE-6TN cells to more type II-like cells. In addition, RLE/Abca3 cells responded well to TGF-beta1 and bleomycin, compounds inducing epithelial-mesenchymal transition in alveolar epithelial cells, than RLE-6TN cells. Thus, RLE/Abca3 cells may be a promising in-vitro model system to analyze and predict drug-induced lung toxicity.
|
